BRCA1 and triple-negative breast carcinoma: Liquiritigenin, on the other hand, has been shown to prevent carcinogenesis in triple-negative breast cancer cells (MDA-MB-231 and BT549) by enhancing breast cancer 1 (BRCA1) transcriptional activity and reducing DNA methyltransferase (DNMT) activity [73].